Companies have long lamented Europe's fragmented capital markets, single-market adoption on pricing and clinical trials, and ...

Iovance Biotherapeutics argues that there is a meaningful opportunity here of more than 8,000 patients diagnosed annually in ...

In the highly regulated world of life sciences, quality isn’t a box to check—it’s a business imperative. For global ...

The upcoming FDA decision for Replimune’s advanced melanoma drug could be a litmus test for the agency's future regulatory ...

For decades, venture capitalists have relied on a tried-and-true recipe to make money in biotech. Now that approach is being ...

The recent uptick in IPOs is an encouraging signal after a drought for much of 2025. Experts point to AI as a driving force ...

While its growth was overshadowed in 2025 by A.I., the biotech sector grew signifcantly and 2026 looks for the trend to ...

Biotech has long been one of the strongest sector stories of the past year, and investors who got there early have been rewarded. As of April 2, 2026, the State Street SPDR S&P Biotech ETF (NYSE:XBI) ...

However, there is one key reason the stock could still deliver outstanding returns over the long run: Its pipeline could help ...

The six companies that have priced initial public offerings so far banked a median of $287.5 million, a figure far surpassing ...

Biotech held steady in early 2026 as M&A buyouts and rotation from the Magnificent Seven lifted IBB relative strength—read ...

The news is the latest example of the biotech industry's struggles in the Bay Area.